[1] MéLANIE DEMERS. Priming of neutrophils toward NETosis promotes tumor growth.[J]. Oncoimmunology, 2016, 5 5: e1134073. DOI:
10.1080/2162402x.2015.1134073[2] JUSTIN E JONES. Protein arginine deiminase 4 (PAD4): Current understanding and future therapeutic potential.[J]. Current opinion in drug discovery & development, 2009, 12 5: 616-627.
[3] PINGXIN LI. PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps.[J]. Journal of Experimental Medicine, 2010, 207 9: 1853-1862. DOI:
10.1084/jem.20100239[4] HAWA RACINE THIAM. NETosis proceeds by cytoskeleton and endomembrane disassembly and PAD4-mediated chromatin decondensation and nuclear envelope rupture.[J]. Proceedings of the National Academy of Sciences of the United States of America, 2020: 7326-7337. DOI:
10.1073/pnas.1909546117[5] ALEXANDER S SAVCHENKO. VWF-mediated leukocyte recruitment with chromatin decondensation by PAD4 increases myocardial ischemia/reperfusion injury in mice.[J]. Blood, 2014, 123 1: 141-148. DOI:
10.1182/blood-2013-07-514992[6] AKARI SUZUKI. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis[J]. Nature genetics, 2003, 34 4: 395-402. DOI:
10.1038/ng1206[7] MARíA TERESA MARTíN MONREAL. Applicability of Small-Molecule Inhibitors in the Study of Peptidyl Arginine Deiminase 2 (PAD2) and PAD4.[J]. Frontiers in Immunology, 2021: 716250. DOI:
10.3389/fimmu.2021.716250[8] TYRILLSHALL DAMIANA . Citrullination of fibrinogen by peptidylarginine deiminase 2 impairs fibrin clot structure[J]. Clinica Chimica Acta, 2020, 501: Pages 6-11. DOI:
10.1016/j.cca.2019.10.033[9] DRES DAMGAARD. Relative efficiencies of peptidylarginine deiminase 2 and 4 in generating target sites for anti-citrullinated protein antibodies in fibrinogen, alpha-enolase and histone H3.[J]. PLoS ONE, 2018: e0203214. DOI:
10.1371/journal.pone.0203214